SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from AML-001, its phase III study of ...
FDA Approves Onureg for Continued Treatment of Adults with AML Who Achieved First Complete Remission
The approval for patients with acute myeloid leukemia was based on data from the phase 3 QUAZAR AML-001 trial, which demonstrated that patients who received Onureg achieved a median overall survival ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new results from the QUAZAR ® AML-001 study presented at the 62 nd American Society of Hematology (ASH) Annual ...
Bristol-Myers Squibb has scored significant overall survival results in a phase 3 trial of its oral maintenance therapy CC-486 in acute myeloid leukaemia patients who have limited treatment options.
QUAZAR AML-001 is a phase 3, international, randomized, double-blind, placebo-controlled study of CC-486 as AML maintenance therapy in patients who achieved first complete remission (CR) or complete ...
Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP). This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not ...
This trial looked azacitidine tablets and best supportive care for acute myeloid leukaemia that was in remission. This means people had no signs of leukaemia after initial treatment. The trial was ...
Edmonton, Alberta--(Newsfile Corp. - April 8, 2022) - Pacylex today announced that data from an investigation of the potential for N-myristoylation inhibition to treat Acute Myeloid Leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results